SPDRS&PPharmaceuticals ETFFind Ratings Reports
- Last Ratings Update:02/28/2017
- Price as of 02/28/2017 :$41.84
- Net Assets:$974.9 Million
- Peer Rank:32 of 35
- Investment Rating:E+
We rate SPDR S&P Pharmaceuticals ETF at E+. Negative factors that influence this rating include a below average total return. The fund invests approximately 100% of its assets in stocks and may be considered for investors seeking a Sector - Health/Biotechnology strategy.
POSITIVES AND RISKS
Total return ranks below peers over the last three years. The SPDR S&P Pharmaceuticals ETF has returned an annual rate of 12.78% since inception. More recently, the fund has generated a total return of 13.83% in the last five years, 0.89% in the last three years, and 2.74% in the last year. How does that compare to other equity funds? In the last five years, it has outperformed 85% of them. It has also outpaced 32% of its competitors on a three year basis and 22% of them over the last year for the period ending 2/28/2017. On a year to date basis, XPH has returned 8.08%.
Downside risk has been above average. XPH has a draw down risk of -70.36%, which is the largest price decline experienced over the last three years. This fund has a three year standard deviation of 26.0%. This fund has experienced excessive volatility in its monthly performance over the last 36 months. As of 2/28/2017, the fund was trading at a price of $41.84, which is 2.4% below its 52-week high of $42.87 and 8.0% above its 52-week low of $38.75.
Low expense ratio helps performance. On total assets of $974.90 million, XPH maintains a low expense ratio compared to its Sector - Health/Biotechnology peers of just 0.35% to cover all operating costs. Brokerage costs for the fund to buy and sell shares are not included in the expense ratio. As XPH is an exchange traded fund, it has no front end or back end load.
The SPDR S&P Pharmaceuticals ETF is managed by John A. Tucker at SSgA Funds Management Inc. This fund is one of 145 SSgA Funds Management Inc exchange-traded funds launched since 12/16/1998 that we track.